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preproGRP transcripts were found in 28% of the blood samples.
The detection of a hematogenic tumor cell spread with preproGRP
in MTC correlated significantly with advanced tumor categories.
CK20 transcripts were detected in 75% of the blood samples of
patients with thyroid carcinoma and distant metastases. More-
over disseminated tumor cells were detected in 21% of the bone
marrow samples with CK20-PCR and 13% with preproGRP (only
for MTC).
Conclusion: Both assays are sensitive enough to detect dissemi-
nated thyroid carcinoma cells in blood and bone marrow sam-
ples. However, the prognostic relevance of these disseminated
tumor cells is not completely understood and has to be addressed
in further investigations.
doi:10.1016/j.ejcsup.2006.04.052
S52. Pdcd4 TARGETS eIF4A TO INHIBIT TRANSLATION,
TRANSCRIPTION, TUMORIGENESIS, AND INVASION
Nancy H. Colburn, Hsin-Sheng Yang, Aaron Jansen. Laboratory of
Cancer Prevention, National Cancer Institute, Frederick, MD 21702,
USA.
Despite its name, Programmed Cell Death 4 (Pdcd4) may or may
not induce apoptosis. Pdcd4 was discovered as a highly expressed
gene in mouse JB6 cells resistant to transformation. Pdcd4 inhib-
its transformation and tumorigenesis, in part by specifically
inhibiting AP-1 dependent transcription. The binding partners
of Pdcd4 are not Jun or Fos proteins but are translation initiation
factors eIF4A and eIF4G. Pdcd4 inhibits translation initiation by
directly binding to translation initiation factor eIF4A and inhibit-
ing its helicase activity. The helicase activity of eIF4A is important
for unwinding 5 0UTR structured mRNAs prior to scanning to the
translational start site. Pdcd4 also interferes with scaffold eIF4G
function. Pdcd4 must interact with eIF4A and inhibit translation
in order to inhibit AP-1 transactivation, as Pdcd4 mutants inacti-
vated for eIF4A binding fail to inhibit AP-1. Recent findings with
K14-driven Pdcd4 expression in mice have established that Pdcd4
inhibits translation of a 5 0UTR-structured mRNA as well as
expression of ‘‘translationally repressed’’ proteins. Pdcd4 inhibits
AP-1 dependent transcription and acts to attenuate papilloma-
genesis and papilloma to carcinoma conversion. Moreover Pdcd4
expression (a) is downregulated with progression in several
human cancer sites, (b) confers sensitivity to certain therapeutic
drugs, and (c) suppresses invasion and motility in human cancer
cell lines. Pdcd4 suppresses cancer cell invasion by targeting the
expression of MAP4K1, an upstream regulator of Jun N-terminal
Kinase signaling, with consequent inhibition of AP-1 dependent
transcription. Thus, activating or mimicking the expression of
Pdcd4 might be an attractive preventive or therapeutic strategy.
Enhancing the interaction of Pdcd4 with eIF4A or targeting down-
stream translational targets may produce the ‘‘desired’’ but not
the ‘‘undesired’’ outcomes achieved with mTOR inhibitors. mTOR
inhibitors repress translation by enhancing the interaction of 4E-
BP with cap binding protein eIF4E but are also immunosuppres-
sive. Pdcd4 appears not to show immunosuppressive activity.
Although we and others have identified translationally repressed
candidates, the functionally significant translational targets of
Pdcd4 are still unknown. Knowing these Pdcd4 targets is impor-
tant for designing prevention strategies. In summary, Pdcd4 is
the first suppressor of tumorigenesis and invasion known to
directly inhibit translation initiation. Translation initiation thus
appears to be a promising molecular target for cancer prevention
and intervention.
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S53. THE ISEL AND BR21 TRIALS – OUTCOMES SIMILAR OR
DIFFERENT?
Nick Thatcher. Christie Hospital, Manchester, UK.
The survival effects of EGFR-TKI therapy have been evaluated in
two Phase III placebo-controlled studies in refractory NSCLC: ISEL
(IRESSA Survival Evaluation in Lung cancer no. = 1692) and BR21
(erlotinib no. = 731).1,2 Gefitinib (Iressa) showed some improve-
ment in survival compared with placebo, but the difference did
not reach statistical significance on the prespecified stratified
log rank test required for registration in either the overall popula-
tion (HR 0.89; p = 0.087; median 5.6 vs. 5.1 months) or in patients
with adenocarcinoma (HR 0.84; p = 0.089; median 6.3 vs. 5.4
months). However, preplanned subgroup analyses showed that
gefitinib significantly prolonged survival in patients of Asian eth-
nicity and in patients who had never smoked. The erlotinib BR21
study had a similar design to ISEL, but demonstrated a statisti-
cally significant overall survival benefit for erlotinib HR = 0.7
p < 0.001 median 6.7 vs. 4.7 months.2 However the 95% confidence
intervals for the HRs overlap ISEL 0.77–1.02 and 0.58–0.85 for BR21
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